INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 134 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2019. The put-call ratio across all filers is 0.10 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,636 | -17.7% | 89 | 0.0% | 0.00% | -33.3% |
| Q2 2023 | $5,635 | +16.9% | 89 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $4,819 | +2.3% | 89 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $4,710 | -32.7% | 89 | -39.9% | 0.00% | -25.0% |
| Q3 2022 | $7,000 | -12.5% | 148 | 0.0% | 0.00% | -20.0% |
| Q2 2022 | $8,000 | 0.0% | 148 | 0.0% | 0.01% | +25.0% |
| Q4 2021 | $8,000 | +33.3% | 148 | 0.0% | 0.00% | +33.3% |
| Q3 2021 | $6,000 | 0.0% | 148 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $6,000 | +20.0% | 148 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $5,000 | -16.7% | 148 | -24.1% | 0.00% | -25.0% |
| Q4 2020 | $6,000 | +20.0% | 195 | 0.0% | 0.00% | -20.0% |
| Q2 2020 | $5,000 | +66.7% | 195 | -43.5% | 0.01% | +150.0% |
| Q3 2019 | $3,000 | -40.0% | 345 | -9.2% | 0.00% | -33.3% |
| Q2 2019 | $5,000 | 0.0% | 380 | 0.0% | 0.00% | -25.0% |
| Q1 2019 | $5,000 | -44.4% | 380 | -3.8% | 0.00% | 0.0% |
| Q3 2018 | $9,000 | – | 395 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |